以前治療された転移性大腸がん患者の全生存期に対するフルーキンチニブとプラセボの効果: FRESCOランダム化臨床試験
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。経口フルクインチニブは,化学療法後に進行する転移性大腸がん (CRC) の患者の全生存期間を有意に改善しました. このVEGFR阻害剤は,進行したCRCの新たな治療法を提供します.
科学分野
- 腫瘍学
- 臨床薬理学
- 胃腸内科
背景
- 転移性大腸がん (CRC) は,患者にとって有効で許容できる治療の選択肢が限られている.
- 転移性CRCの第3線または後の治療には,新しい治療戦略が必要です.
研究 の 目的
- 血管内皮成長因子受容体 (VEGFR) 阻害剤であるフルクインチニブの有効性と安全性を評価する.
- 転移性CRCの患者に対する第3線または後の治療としてフルクインチニブを評価する.
主な方法
- FRESCO試験は,中国で行われた3相,ランダム化,ダブルブラインド,プラセボ対照試験でした.
- 416人の転移性CRC患者で,少なくとも2回の化学療法とVEGFR阻害剤の治療を受けていない患者は,フラクインチニブまたはプラセボにランダムに割り当てられました.
- 主要エンドポイントは全生存率であり,次要エンドポイントは進行性生存率と客観的な応答率であった.
主要な成果
- フルクインチニブ (9. 3ヶ月) とプラセボ (6. 6ヶ月) の平均全生存期間は有意に長かった (HR,0. 65;P < . 001).
- 進行のない生存期間の中央値も有意に増加しました (3. 7ヶ月対1. 8ヶ月;HR,0. 26;P < . 001).
- フルクインチニブ患者の61. 2%,プラセボ患者の19. 7%で発生した.
結論
- 経口フルクインチニブは,中国人の転移性CRC患者の全生存期間をプラセボと比較して統計的に有意に増加させた.
- フルクインチニブは,前回の化学療法で進行した進行性CRCの患者にとって有望な治療法です.
- 中国国外での様々な患者集団におけるフルクインチニブの有効性を評価するために,さらなる研究が必要である.
関連する概念動画
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
The placebo effect is commonly described in terms of testing the effectiveness of a new medication. Imagine that you work in a pharmaceutical company, and you think you have a new drug that is effective in treating depression. To demonstrate that your medication is effective, you run...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...